1687-51-0 | 2-Aminoquinazoline

Packsize	Purity	Availability	Price	Discounted Price
100mg	98%	in stock	$6.00	$4.00
250mg	98%	in stock	$8.00	$6.00
1g	98%	in stock	$21.00	$15.00
5g	98%	in stock	$98.00	$69.00
10g	98%	in stock	$195.00	$137.00
25g	98%	in stock	$487.00	$341.00

Description

• Catalog Number: AA90821
• Chemical Name: 2-Aminoquinazoline
• CAS Number: 1687-51-0
• Molecular Formula: C8H7N3
• Molecular Weight: 145.1613
• MDL Number: MFCD00956186
• SMILES: Nc1ncc2c(n1)cccc2

Computed Properties

• Complexity: 137
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 11
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 1
• XLogP3: 1.3

Literature

• An aminoquinazoline inhibitor of the essential bacterial cell wall synthetic enzyme GlmU has a unique non-protein-kinase-like binding mode.

  The Biochemical journal 20120915

• Substituted aminopyrimidine protein kinase B (PknB) inhibitors show activity against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20120501

• Discovery of novel aminoquinazolin-7-yl 6,7-dihydro-indol-4-ones as potent, selective inhibitors of heat shock protein 90.

  Bioorganic & medicinal chemistry letters 20120401

• Synthesis of aminoquinazoline derivatives and their antiproliferative activities against melanoma cell line.

  Bioorganic & medicinal chemistry letters 20101001

• Anticonvulsant Activity of Schiff Bases of 3-Amino-6,8-dibromo-2-phenyl-quinazolin-4(3H)-ones.

  Indian journal of pharmaceutical sciences 20100101

• 2-(5,6-Di-hydro-benzimidazolo[1,2-c]quinazolin-6-yl)aniline methanol solvate.

  Acta crystallographica. Section E, Structure reports online 20090701

• Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100.

  British journal of cancer 20080520

• Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.

  Journal of medicinal chemistry 20080327

• From arylureas to biarylamides to aminoquinazolines: discovery of a novel, potent TRPV1 antagonist.

  Bioorganic & medicinal chemistry letters 20061001

• Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.

  Journal of medicinal chemistry 20060921

• The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR).

  Journal of medicinal chemistry 20060615

• Nitrenes, diradicals, and ylides. Ring expansion and ring opening in 2-quinazolylnitrenes.

  The Journal of organic chemistry 20060526

• 2-Aminoquinazoline inhibitors of cyclin-dependent kinases.

  Bioorganic & medicinal chemistry letters 20050901

• Multiple mechanisms of action of ZR2002 in human breast cancer cells: a novel combi-molecule designed to block signaling mediated by the ERB family of oncogenes and to damage genomic DNA.

  International journal of cancer 20041110

• Identification and specificity studies of small-molecule ligands for SH3 protein domains.

  Journal of medicinal chemistry 20041021

• Characterization of inhibitor binding sites of mitochondrial complex I using fluorescent inhibitor.

  Biochimica et biophysica acta 20030818

• Design of triple helix forming C-glycoside molecules.

  Journal of the American Chemical Society 20030226

• Physical methods to determine the binding mode of putative ligands for hepatitis C virus NS3 helicase.

  Analytical biochemistry 20021015